Off-ramp planner
Life after a GLP-1 — planned, not guessed
The decision almost no one prepares you for: continue, step down, or stop. This won’t tell you what to do — it shows the real evidence, the honest trade-offs, and the exact questions to take to your clinician. No doses, no advice about your situation.
Where are you?
What matters most? (pick any)
First, the reality: what happens if you stop
Your three paths
Continue
Established that it holds loss
In randomized withdrawal trials (STEP 4, SURMOUNT-4) people who kept taking the medicine held their loss; it’s the most reliable way to maintain. Trade-off: ongoing cost, ongoing side-effect management, and it treats obesity as the chronic condition it is.
Step down
Limited evidence on how
Some people and clinicians try a lower maintenance approach. The honest state of evidence: trials studied *continuing* vs *stopping*, not an optimal taper — so “how to step down” is a clinician decision, not a settled protocol. This page gives no doses.
Stop
Regain is the documented default
Stopping is followed, on average, by substantial regain (~two-thirds within a year) as appetite returns — because the drug was managing the biology, not curing it. Not a failure; expected physiology. If you stop, a maintenance plan is what changes the trajectory.
The levers that actually move the trajectory
- supported-but-limitedAdequate protein
Higher protein during and after weight loss helps preserve lean (muscle) mass versus lower intake. Targets are individual — frame them with a clinician or dietitian.
- emergingResistance training
Building and keeping muscle was the habit that best survived treatment cessation in the maintenance trial. Even a “minimum effective” strength habit matters.
- emergingMaintained activity
People who kept moving after stopping held their loss better than those who relied on the medicine alone. Activity has to be deliberate — the weight loss doesn’t create it.
- supported-but-limitedA planned transition (not cold-turkey)
Stopping with a plan — habits in place first, clinician aligned — beats stopping abruptly and hoping. For people with diabetes, an unplanned gap is itself a risk to discuss first.
- established (process)Coverage & cost options
If cost is the driver, a covered indication, the 2026 Medicare Bridge, or a manufacturer program may change the math before you stop. See the Coverage Checker.
- establishedMonitoring what matters
Track function and the markers your clinician cares about (not just the scale) through any change, so you catch drift early.
Questions to take to your clinician
- Given my situation, what are my real options — continue, step down, or stop — and the trade-offs of each for me?
- If we change anything, what should I watch for, and how do we prevent or catch regain early?
- How do we protect my muscle and function through this — protein, training, monitoring?
- If cost is the issue, what covered options or assistance programs apply before I stop?
- I have other conditions (e.g. diabetes) — is an interruption itself a risk, and how do we manage it?
- What would make us reconsider — restart, or change course — and how soon would we know?